Insider · CIK 0001810417
Christopher Ryan Sullivan
Files at AVTX (Avalo Therapeutics, Inc.). First filing Apr 3, 2026, latest Sep 18, 2026.
In brief
Christopher Ryan Sullivan files SEC Form 4 as CFO at AVTX (Avalo Therapeutics, Inc.). Since Apr 3, 2026, Christopher Ryan Sullivan has reported 0 open-market buys worth $0 and 7 open-market sells worth $3.7M, the latest filed on Sep 18, 2026.
A track record needs three past buys with six months of prices behind them; Christopher Ryan Sullivan has 0, so none is measured yet.
The newest scored trade: sold $202k of AVTX on Sep 16, 2026, filed Sep 18, 2026, scored 4 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 7 sells worth $3.7M.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
AVTX: Avalo Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 4Weak | Avalo Therapeutics, Inc. | $202k 12,394 shares | -24% | +70% from low-28% from high | |
| 12Weak | Avalo Therapeutics, Inc. | $179k 10,185 shares | -20% | +76% from low-25% from high | |
| 47Moderate | Avalo Therapeutics, Inc. | $1.5M 72,725 shares | -89% | +124% from low-13% from high | |
| 39Weak | Avalo Therapeutics, Inc. | $449k 18,606 shares | -98% | +537% from low0% from high | |
| 46Moderate | Avalo Therapeutics, Inc. | $949k 47,000 shares | -99% | +508% from low0% from high | |
| 49Moderate | Avalo Therapeutics, Inc. | $223k 16,915 shares | -98% | +268% from low-34% from high | |
| 33Weak | Avalo Therapeutics, Inc. | $271k 15,959 shares | -48% | +365% from low-16% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Aug 18, 2026 | AVTX AVALO THERAPEUTICS, INC. | 31,031 0.06% of outstanding | $622k | Aug 18, 2026 | $75k |
| Aug 17, 2026 | AVTX AVALO THERAPEUTICS, INC. | 3,749 0.01% of outstanding | $75k | Aug 17, 2026 | none |
| Aug 17, 2026 | AVTX AVALO THERAPEUTICS, INC. | 70,709 0.13% of outstanding | $1.4M | Aug 17, 2026 | none |
| May 7, 2026 | AVTX AVALO THERAPEUTICS, INC. | 18,606 0.08% of outstanding | $406k | May 7, 2026 | $1.4M |
| May 6, 2026 | AVTX AVALO THERAPEUTICS, INC. | 47,000 0.21% of outstanding | $764k | May 6, 2026 | $493k |
| Apr 29, 2026 | AVTX AVALO THERAPEUTICS, INC. | 16,915 0.07% of outstanding | $218k | Apr 29, 2026 | $271k |
| Apr 1, 2026 | AVTX AVALO THERAPEUTICS INC | 15,959 0.07% of outstanding | $238k | Apr 1, 2026 | none |
Transactions
Every row this insider has filed, 42 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 16, 2026 | AVTX Avalo Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +12,394 | $9.88 | $122k | 52,294 | 25 d ago |
| Sep 16, 2026 | AVTX Avalo Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -12,394 | $16.33 | $202k | 39,900 | 25 d ago |
| Sep 16, 2026 | AVTX Avalo Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -12,394 | $0.00 | $0 | 83,848 | 25 d ago |
| Sep 10, 2026 | AVTX Avalo Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +10,185 | $8.04 | $82k | 50,085 | 32 d ago |
| Sep 10, 2026 | AVTX Avalo Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -10,185 | $17.62 | $179k | 39,900 | 32 d ago |
| Sep 10, 2026 | AVTX Avalo Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -10,185 | $0.00 | $0 | 105,815 | 32 d ago |
| Aug 17, 2026 | AVTX Avalo Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +37,945 | $9.88 | $375k | 78,718 | Aug 19, 2026 |
| Aug 17, 2026 | AVTX Avalo Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +2,876 | $9.88 | $28k | 81,594 | Aug 19, 2026 |
| Aug 17, 2026 | AVTX Avalo Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -37,945 | $19.85 | $753k | 43,649 | Aug 19, 2026 |
| Aug 17, 2026 | AVTX Avalo Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -3,749 | $19.94 | $75k | 39,900 | Aug 19, 2026 |
| Aug 18, 2026 | AVTX Avalo Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +31,031 | $9.88 | $307k | 70,931 | Aug 19, 2026 |
| Aug 18, 2026 | AVTX Avalo Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -31,031 | $20.05 | $622k | 39,900 | Aug 19, 2026 |
| Aug 17, 2026 | AVTX Avalo Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -37,945 | $0.00 | $0 | 130,149 | Aug 19, 2026 |
| Aug 17, 2026 | AVTX Avalo Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -2,876 | $0.00 | $0 | 127,273 | Aug 19, 2026 |
| Aug 18, 2026 | AVTX Avalo Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -31,031 | $0.00 | $0 | 96,242 | Aug 19, 2026 |
| Jun 10, 2026 | AVTX Avalo Therapeutics, Inc. | FTax withholding Common Stock | -138 | $13.10 | $1,808 | 40,773 | Jun 12, 2026 |
| May 21, 2026 | AVTX Avalo Therapeutics, Inc. | AGrant or award Common Stock | +39,900 | $0.00 | $0 | 40,323 | May 26, 2026 |
| May 7, 2026 | AVTX Avalo Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +18,606 | $9.88 | $184k | 19,029 | May 11, 2026 |
| May 7, 2026 | AVTX Avalo Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -18,606 | $24.12 | $449k | 423 | May 11, 2026 |
| May 7, 2026 | AVTX Avalo Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -18,606 | $0.00 | $0 | 168,094 | May 11, 2026 |
| May 6, 2026 | AVTX Avalo Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +47,000 | $8.04 | $378k | 47,423 | May 7, 2026 |
| May 6, 2026 | AVTX Avalo Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -13,834 | $18.55 | $257k | 33,589 | May 7, 2026 |
| May 6, 2026 | AVTX Avalo Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -12,347 | $19.28 | $238k | 21,242 | May 7, 2026 |
| May 6, 2026 | AVTX Avalo Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -2,700 | $20.76 | $56k | 18,542 | May 7, 2026 |
| May 6, 2026 | AVTX Avalo Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -9,219 | $21.37 | $197k | 9,323 | May 7, 2026 |
| May 6, 2026 | AVTX Avalo Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -8,900 | $22.57 | $201k | 423 | May 7, 2026 |
| May 6, 2026 | AVTX Avalo Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -47,000 | $0.00 | $0 | 116,000 | May 7, 2026 |
| Apr 29, 2026 | AVTX Avalo Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -8,458 | $13.09 | $111k | 8,880 | May 1, 2026 |
| Apr 30, 2026 | AVTX Avalo Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -8,457 | $13.23 | $112k | 423 | May 1, 2026 |
| Apr 1, 2026 | AVTX Avalo Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -500 | $15.86 | $7,929 | 32,797 | Apr 3, 2026 |
| Apr 1, 2026 | AVTX Avalo Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -7,479 | $16.83 | $126k | 25,318 | Apr 3, 2026 |
| Apr 2, 2026 | AVTX Avalo Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -6,200 | $17.02 | $106k | 19,118 | Apr 3, 2026 |
| Apr 2, 2026 | AVTX Avalo Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -1,780 | $17.57 | $31k | 17,338 | Apr 3, 2026 |
| Mar 28, 2026 | AVTX Avalo Therapeutics, Inc. | MOption exercise Common Stock | +24,200 | - | - | 41,538 | Mar 31, 2026 |
| Mar 28, 2026 | AVTX Avalo Therapeutics, Inc. | FTax withholding Common Stock | -8,241 | $13.89 | $114k | 33,297 | Mar 31, 2026 |
| Mar 28, 2026 | AVTX Avalo Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -24,200 | $0.00 | $0 | 24,200 | Mar 31, 2026 |
| Feb 26, 2026 | AVTX Avalo Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +105,000 | $0.00 | $0 | 105,000 | Mar 2, 2026 |
| Dec 10, 2025 | AVTX Avalo Therapeutics, Inc. | FTax withholding Common Stock | -155 | $4.10 | $636 | 17,338 | Dec 12, 2025 |
| Mar 28, 2025 | AVTX Avalo Therapeutics, Inc. | MOption exercise Common Stock | +24,200 | - | - | 24,206 | Apr 1, 2025 |
| Mar 28, 2025 | AVTX Avalo Therapeutics, Inc. | FTax withholding Common Stock | -7,285 | $8.46 | $62k | 16,921 | Apr 1, 2025 |
| Mar 28, 2025 | AVTX Avalo Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -24,200 | $0.00 | $0 | 48,400 | Apr 1, 2025 |
| Jan 28, 2025 | AVTX Avalo Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +163,000 | $0.00 | $0 | 163,000 | Jan 30, 2025 |
Questions about Christopher Ryan Sullivan
Answered from the filings on this page, as of the latest one.
Is Christopher Ryan Sullivan buying or selling?
In the last 12 months Christopher Ryan Sullivan reported 0 open-market buys worth $0 and 7 open-market sells worth $3.7M on SEC Form 4; the latest was sold $202k of AVTX on Sep 16, 2026. Grants, option exercises and tax withholding are not counted.
How did Christopher Ryan Sullivan's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Christopher Ryan Sullivan has 0.
Where does Christopher Ryan Sullivan file Form 4?
Christopher Ryan Sullivan has filed Form 4 at AVTX (Avalo Therapeutics, Inc.) as Chief Financial Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.